Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Yanglin Guo

Internal Medicine Jackson, MS Medical Doctor

NPI 1760893689 CMS profile 1182046

2500 N State St, Jackson, MS 39216

Open in the dashboard

General payments

$10,177

388 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Yanglin Guo of Jackson, MS is reported in the CMS Open Payments database as having received $10,177 across 388 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,910 81
2024 General $2,593 62
2023 General $896 39
2022 General $1,346 47
2021 General $1,390 69
2020 General $695 26
2019 General $1,346 64

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Yanglin Guo
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Yanglin Guo were reported at $1,910. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Yanglin Guo Internal Medicine median Middle half National median
2019 $1,346 $159 $48–$570 $163
2020 $695 $119 $33–$402 $114
2021 $1,390 $135 $37–$521 $132
2022 $1,346 $141 $42–$496 $149
2023 $896 $149 $45–$519 $160
2024 $2,593 $154 $47–$537 $164
2025 $1,910 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,712 54 payments
  2. Intuitive Surgical, Inc. $1,180 7 payments
  3. GlaxoSmithKline, LLC. $984 47 payments
  4. Actelion Pharmaceuticals US, Inc. $970 37 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $809 46 payments
  6. Pfizer Inc. $618 36 payments
  7. AbbVie, Inc. $408 21 payments
  8. Regeneron Healthcare Solutions, Inc. $365 13 payments
  9. Pulmonx Corporation $285 8 payments
  10. Merck Sharp & Dohme Corporation $278 13 payments
  11. Other $2,567 106 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,163 385 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,000 1 payment
  3. Education $14 2 payments
Products named General payments · program years 2019–2025
  1. Da Vinci Surgical System $1,180 7 payments
  2. UPTRAVI $868 37 payments
  3. TRELEGY ELLIPTA $717 42 payments
  4. OFEV $690 39 payments
  5. ELIQUIS $577 34 payments
  6. FASENRA $529 23 payments
  7. BREZTRI $406 13 payments
  8. AVYCAZ $358 18 payments
  9. OPSUMIT $332 13 payments
  10. DUPIXENT $320 11 payments
  11. Other $6,375 245 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 67 billing codes

Paid by Medicare

$91,092

Medicare's payments for the services billed

Medicare patients

340

Average age 68

Services billed

1,135

163 women, 177 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 49%
Diabetes 46%
Heart failure 41%
Ischemic heart disease 41%
Chronic kidney disease 40%
COPD 39%
Depression 36%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $231
$231 — —
OFEV
  • Boehringer Ingelheim Pharmaceuticals, Inc. $170
$170 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $145
$145 — —
ULTOMIRIS
  • Alexion Pharmaceuticals, Inc. $135
$135 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $133
$133 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

388 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record